Alkylxanthines as adenosine receptor antagonists and membrane phosphodiesterase inhibitors in central nervous tissue: evaluation of structure-activity relationships.
D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases / Q000037:antagonists & inhibitors*; D000241:Adenosine / Q000031:analogs & derivatives / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000187:drug effects*; D002462:Cell Membrane / Q000201:enzymology; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D009708:Nucleotidases / Q000037:antagonists & inhibitors; D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases; D051381:Rats; D011956:Receptors, Cell Surface / Q000187:drug effects*; D011983:Receptors, Purinergic; D013329:Structure-Activity Relationship; D013574:Synaptosomes / Q000378:metabolism; D014970:Xanthines / Q000494:pharmacology*
D010726:Phosphodiesterase Inhibitors; D011956:Receptors, Cell Surface; D011983:Receptors, Purinergic; D014970:Xanthines; C027513:N(6)-cyclohexyladenosine; D009708:Nucleotidases; D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases; D010727:Phosphoric Diester Hydrolases; D000241:Adenosine